[{"address1": "Avenida de los Reyes, 1", "address2": "Pol. Industrial La Mina \u2013 Norte Colmenar Viejo", "city": "Madrid", "zip": "28770", "country": "Spain", "phone": "34 91 846 60 00", "fax": "34 91 846 60 01", "website": "https://www.pharmamar.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.", "fullTimeEmployees": 509, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jose Maria Fernandez Sousa-Faro Ph.D.", "title": "Founder, Executive Chairman, CEO & President", "fiscalYear": 2015, "totalPay": 328607, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Pedro Francisco Fernandez Puentes", "title": "Executive Vice-Chairman", "fiscalYear": 2015, "totalPay": 138596, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Juan Carlos-Torres Carretero", "age": 74, "title": "Founder", "yearBorn": 1949, "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mar\u00eda Luisa de Francia Caballero", "title": "Chief Financial Officer", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Jos\u00e9 Luis Moreno Martinez-Losa", "title": "Head of Capital Markets & Investor Relations", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Juan Gomez Pulido", "title": "General Counsel & Secretary of the Board of Directors", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Sandra Llamera Sanchez", "title": "Global Compliance Head", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Lara  Vadillo", "title": "Communication Director", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Bel\u00e9n Sopes\u00e9n Veramendi Ph.D.", "title": "Director of Corporate Development", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Luis Rup\u00e9rez Cuenca", "title": "Director of Human Resources & IT", "fiscalYear": 2015, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 9, "compensationRisk": 6, "shareHolderRightsRisk": 7, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1451520000, "maxAge": 86400, "priceHint": 2, "previousClose": 31.15, "open": 31.15, "dayLow": 31.15, "dayHigh": 31.15, "regularMarketPreviousClose": 31.15, "regularMarketOpen": 31.15, "regularMarketDayLow": 31.15, "regularMarketDayHigh": 31.15, "dividendRate": 0.7, "dividendYield": 0.0155, "exDividendDate": 1718150400, "payoutRatio": 5.7595, "beta": 0.199, "volume": 25, "regularMarketVolume": 25, "averageVolume": 8, "averageVolume10days": 10, "averageDailyVolume10Day": 10, "bid": 44.55, "ask": 48.38, "bidSize": 29200, "askSize": 40700, "marketCap": 782364544, "fiftyTwoWeekLow": 26.85, "fiftyTwoWeekHigh": 46.26, "priceToSalesTrailing12Months": 4.9266667, "fiftyDayAverage": 35.339, "twoHundredDayAverage": 35.68672, "trailingAnnualDividendRate": 0.65, "trailingAnnualDividendYield": 0.020866774, "currency": "USD", "enterpriseValue": 691732928, "profitMargins": -0.011089999, "floatShares": 13611946, "sharesOutstanding": 17394900, "heldPercentInsiders": 0.21392, "heldPercentInstitutions": 0.07751, "bookValue": 10.342, "priceToBook": 4.3415203, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": -0.754, "netIncomeToCommon": -1761000, "trailingEps": -0.11, "lastSplitFactor": "1:12", "lastSplitDate": 1595376000, "enterpriseToRevenue": 4.356, "enterpriseToEbitda": -111.552, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "PHMMF", "underlyingSymbol": "PHMMF", "shortName": "PHARMA MAR SA", "longName": "Pharma Mar, S.A.", "firstTradeDateEpochUtc": 1456237800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "d5339238-853b-3799-8d61-3611d4b97a14", "gmtOffSetMilliseconds": -14400000, "currentPrice": 44.9, "recommendationKey": "none", "totalCash": 135147008, "totalCashPerShare": 7.706, "ebitda": -6201000, "totalDebt": 39383000, "quickRatio": 1.88, "currentRatio": 2.55, "totalRevenue": 158802000, "debtToEquity": 21.713, "revenuePerShare": 9.054, "returnOnAssets": -0.017029999, "returnOnEquity": -0.00899, "freeCashflow": -21768124, "operatingCashflow": -9578000, "earningsGrowth": -0.748, "revenueGrowth": -0.072, "grossMargins": 0.93416, "ebitdaMargins": -0.039049998, "operatingMargins": 0.0091699995, "financialCurrency": "EUR", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]